Skip to main content

Table 1 Patient characteristics

From: Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma

Characteristic

Overall cohort [12]

Heterogeneity study

Number of patients

 

98

27

Male patients (n, %)

 

75 (77%)

23 (85%)

Median age (years)

 

59 (range 37–78)

59 (range 34–73)

MSK risk group

Intermediate

70 (71%)

18 (67%)

Poor

28 (29%)

9 (33%)

Nephrectomy

Yes

62 (63%)

16 (59%)

Organ sites affected by metastases

1

30 (31%)

8 (30%)

2

39 (40%)

13 (48%)

3+

29 (29%)

6 (22%)

  1. MSK Memorial Sloan Kettering [22]
  2. Characteristics of all 98 patients included into the three phase II trials compared to those of the 27 patients in the radiological heterogeneity substudy
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us